🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Helen X. Chen

National Cancer Institute

ORCID: 0000-0001-9959-8417
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

4in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100.v1
Top 100%
0DataRank
Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Papers

Driven by 15 papers — median percentile 0. Top paper: “Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers”.

Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers

Journal of Clinical Investigation(2021)10.1172/jci152670
N/A
2.1DataRank · unranked
86 citations

Leslie Cope, Amanda N. Ruggieri, Robert A. Anders, Anne M. Noonan, Laura W. Goff +24 more

Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0709
N/A
0.652DataRank · unranked
20 citations

R. Taylor Sundby, Donna Bernstein, John Glod, Rosandra N. Kaplan, Marielle E. Yohe +17 more

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3135
N/A
0.546DataRank · unranked
37 citations

T. Khanh, Jeong Eun Kim, James M. Cleary, Aparna R. Parikh, Oladapo Yeku +26 more

A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3817
N/A
0.477DataRank · unranked
23 citations

Rachel S. Heise, Kristen Ganjoo, Elizabeth J. Davis, Suzanne George, Melissa Burgess +16 more

Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma

npj Precision Oncology(2025)10.1038/s41698-024-00798-1
N/A
0.303DataRank · unranked
5 citations

Eleanor Cano-Linson, Young Kwang Chae, Shiruyeh Schokrpur, Christopher D. Lao, Benjamin Powers +13 more

A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps9638
N/A
0DataRank · unranked
1 citations

Richard D. Hall, Andreas Saltos, Gregory A. Otterson, Ming Tan, Sacha Gnjatic +5 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100.v1
Top 100%
0DataRank
Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07551-z
N/A
0DataRank · unranked
12 citations

H. Boutrid, Mahmoud Kassem, Mahmoud Abdel‐Rasoul, Cynthia Timmers, Maryam B. Lustberg +19 more

SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0606
N/A
0DataRank · unranked
11 citations

Megan Othus, Sandip Pravin Patel, Kelly J. Wilkinson, Emily M. Whitman-Purves, Jayanthi Lea +21 more

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1957
N/A
0DataRank · unranked
6 citations

Lucy Corthell, Sandip Pravin Patel, Robert P. Edwards, Jennifer Scalici, Hye Sung Kim +10 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100
Top 100%
0DataRank
Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.11503
N/A
0DataRank · unranked
10 citations

Karla V. Ballman, Kristen Ganjoo, Elizabeth J. Davis, Jeffrey A. Morgan, Gabriel Tinoco +15 more

Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1123
N/A
0DataRank · unranked
13 citations

Mark Yarchoan, Subir Goyal, Yuan Liu, Elad Sharon, Helen X. Chen +7 more

Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6531336
Top 100%
0DataRank
Top 100%0 citations

Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao +29 more

Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6531336.v1
Top 100%
0DataRank
Top 100%0 citations

Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao +29 more